Biocept (BIOC) Tops Q4 EPS by 15c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pre-Open Stock Movers 03/26: (ALDX) (BBBY) (BIOC) Higher; (CCL) (MYOK) (RCL) Lower (more...)
March 26, 2019 9:28 AM EDTToday's Pre-Open Movers
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) 66.8% HIGHER; announced positive results from the Phase 3 ALLEVIATE Trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. The clinical trial met the primary endpoint and the key secondary endpoint for both concentrations of... More
Maxim Group Starts Biocept (BIOC) at Buy
March 26, 2019 7:37 AM EDTMaxim Group analyst Jason McCarthy initiates coverage on Biocept (NASDAQ: BIOC) with a Buy rating and a price target of $3.00.
We are initiating coverage of Biocept with a Buy rating and $3 price target. Biocepts Target Selector is a liquid biopsy platform which, in addition to providing actionable data based on circulating tumor DNA (ctDNA) analysis, incorporates... More